NO3058793T3 - - Google Patents
Info
- Publication number
- NO3058793T3 NO3058793T3 NO15704618A NO15704618A NO3058793T3 NO 3058793 T3 NO3058793 T3 NO 3058793T3 NO 15704618 A NO15704618 A NO 15704618A NO 15704618 A NO15704618 A NO 15704618A NO 3058793 T3 NO3058793 T3 NO 3058793T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361824739P | 2013-05-17 | 2013-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO3058793T3 true NO3058793T3 (no) | 2018-03-17 |
Family
ID=51897679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO15704618A NO3058793T3 (no) | 2013-05-17 | 2015-01-28 |
Country Status (19)
Country | Link |
---|---|
US (1) | US9643982B2 (no) |
EP (2) | EP3330272B1 (no) |
AR (1) | AR096332A1 (no) |
AU (1) | AU2014267951A1 (no) |
CY (1) | CY1119842T1 (no) |
DK (1) | DK2997033T3 (no) |
ES (1) | ES2656696T3 (no) |
HK (1) | HK1248685A1 (no) |
HR (1) | HRP20180081T1 (no) |
HU (1) | HUE036384T2 (no) |
LT (1) | LT2997033T (no) |
ME (1) | ME02977B (no) |
NO (1) | NO3058793T3 (no) |
PL (1) | PL2997033T3 (no) |
PT (1) | PT2997033T (no) |
RS (1) | RS56701B1 (no) |
SI (1) | SI2997033T1 (no) |
TW (1) | TWI656122B (no) |
WO (1) | WO2014183532A1 (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016027879A1 (ja) | 2014-08-22 | 2016-02-25 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
TWI520963B (zh) * | 2014-12-24 | 2016-02-11 | 國立清華大學 | 1,9-二氮萉衍生物及其製法 |
WO2017113288A1 (en) * | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
JOP20190130A1 (ar) * | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
BR112019011074B1 (pt) * | 2016-12-02 | 2021-01-19 | Merck Sharp & Dohme Corp. | Compostos heterocíclicos tricíclicos inibidores de hiv integrase, composição que oscompreende e uso dos mesmos |
MA52367A (fr) * | 2018-04-27 | 2021-03-03 | Merck Sharp & Dohme | Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih |
EP3805220A4 (en) | 2018-05-31 | 2022-01-05 | Shionogi & Co., Ltd | POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES |
US11453669B2 (en) | 2018-05-31 | 2022-09-27 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative |
EP3801543A4 (en) | 2018-06-05 | 2022-03-02 | Merck Sharp & Dohme Corp. | HETEROCYCLIC TRICYCLIC COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS |
SI3810283T1 (sl) | 2018-06-21 | 2023-10-30 | F. Hoffmann-La Roche Ag | Trdne oblike tartratne soli 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2H-pirido(3,4-b)indol-2-il)-2,2- difluoropropan-1-ola, postopek za njihovo pripravo in metode njihove uporabe pri zdravljenju raka |
US11084832B2 (en) | 2019-03-22 | 2021-08-10 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
TW202133858A (zh) | 2019-11-28 | 2021-09-16 | 日商鹽野義製藥股份有限公司 | 以組合整合酶阻礙劑及抗hiv藥為特徵之hiv感染症的預防及治療用醫藥 |
PE20221569A1 (es) | 2020-02-24 | 2022-10-06 | Gilead Sciences Inc | Compuestos tetraciclicos para el tratamiento de infecciones por vih |
AU2022210247A1 (en) | 2021-01-19 | 2023-08-17 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0211750A (pt) | 2001-08-10 | 2004-10-13 | Shionogi & Co | Agente antiviral |
EP1441734B1 (en) | 2001-10-26 | 2007-02-28 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
CN1700918B (zh) | 2001-10-26 | 2011-06-08 | P·安杰莱蒂分子生物学研究所 | 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂 |
DE60315796T2 (de) | 2002-01-17 | 2008-06-05 | Merck & Co., Inc. | Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen |
AU2003292437A1 (en) | 2002-12-27 | 2004-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Tetrahydro-4h-pyrido(1,2-a)pyrimidines and related compounds useful as hiv integrase inhibitors |
WO2004062613A2 (en) | 2003-01-13 | 2004-07-29 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
EA200601654A1 (ru) * | 2004-03-09 | 2007-02-27 | Мерк Энд Ко., Инк. | Ингибиторы интегразы вич |
CN1930161A (zh) * | 2004-03-09 | 2007-03-14 | P·安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
US7619086B2 (en) | 2004-03-09 | 2009-11-17 | Merck & Co., Inc. | HIV integrase inhibitors |
US7820680B2 (en) * | 2004-03-09 | 2010-10-26 | Merck & Co., Inc. | HIV integrase inhibitors |
US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
US7157447B2 (en) | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
US7173022B2 (en) | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
WO2006103399A1 (en) | 2005-03-31 | 2006-10-05 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
US7494984B2 (en) | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
WO2007059125A2 (en) | 2005-11-15 | 2007-05-24 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
US7902182B2 (en) | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
WO2007143446A1 (en) | 2006-05-30 | 2007-12-13 | Bristol-Myers Squibb Company | Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors |
US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
MX2012004426A (es) | 2009-10-13 | 2012-07-30 | Elanco Animal Health Ireland | Inhibidores macrociclicos de integrasa. |
PE20130010A1 (es) * | 2010-02-26 | 2013-02-05 | Japan Tobacco Inc | Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih |
CN102958935B (zh) | 2010-04-02 | 2015-12-09 | 爱尔兰詹森科学公司 | 大环整合酶抑制剂 |
-
2014
- 2014-04-18 ES ES14798188.0T patent/ES2656696T3/es active Active
- 2014-04-18 RS RS20180010A patent/RS56701B1/sr unknown
- 2014-04-18 DK DK14798188.0T patent/DK2997033T3/da active
- 2014-04-18 HU HUE14798188A patent/HUE036384T2/hu unknown
- 2014-04-18 US US14/892,754 patent/US9643982B2/en active Active
- 2014-04-18 PT PT147981880T patent/PT2997033T/pt unknown
- 2014-04-18 ME MEP-2018-4A patent/ME02977B/me unknown
- 2014-04-18 LT LTEP14798188.0T patent/LT2997033T/lt unknown
- 2014-04-18 WO PCT/CN2014/075685 patent/WO2014183532A1/en active Application Filing
- 2014-04-18 EP EP17201148.8A patent/EP3330272B1/en active Active
- 2014-04-18 PL PL14798188T patent/PL2997033T3/pl unknown
- 2014-04-18 SI SI201430563T patent/SI2997033T1/en unknown
- 2014-04-18 AU AU2014267951A patent/AU2014267951A1/en not_active Abandoned
- 2014-04-18 EP EP14798188.0A patent/EP2997033B1/en active Active
- 2014-05-15 TW TW103117219A patent/TWI656122B/zh not_active IP Right Cessation
- 2014-05-16 AR ARP140101973A patent/AR096332A1/es not_active Application Discontinuation
-
2015
- 2015-01-28 NO NO15704618A patent/NO3058793T3/no unknown
-
2018
- 2018-01-16 HR HRP20180081TT patent/HRP20180081T1/hr unknown
- 2018-01-24 CY CY20181100097T patent/CY1119842T1/el unknown
- 2018-06-26 HK HK18108172.3A patent/HK1248685A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
ME02977B (me) | 2018-10-20 |
EP2997033A4 (en) | 2016-10-26 |
EP3330272B1 (en) | 2021-02-17 |
EP2997033A1 (en) | 2016-03-23 |
HRP20180081T1 (hr) | 2018-02-23 |
US20160108059A1 (en) | 2016-04-21 |
SI2997033T1 (en) | 2018-04-30 |
HK1248685A1 (zh) | 2018-10-19 |
EP2997033B1 (en) | 2017-11-15 |
AU2014267951A1 (en) | 2015-11-19 |
LT2997033T (lt) | 2018-02-12 |
HUE036384T2 (hu) | 2018-07-30 |
EP3330272A1 (en) | 2018-06-06 |
DK2997033T3 (da) | 2018-01-29 |
AR096332A1 (es) | 2015-12-23 |
TWI656122B (zh) | 2019-04-11 |
WO2014183532A1 (en) | 2014-11-20 |
US9643982B2 (en) | 2017-05-09 |
PT2997033T (pt) | 2018-01-25 |
ES2656696T3 (es) | 2018-02-28 |
PL2997033T3 (pl) | 2018-04-30 |
CY1119842T1 (el) | 2018-06-27 |
TW201524978A (zh) | 2015-07-01 |
RS56701B1 (sr) | 2018-03-30 |